Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

NCT02202551 is registered in ClinicalTrials.gov with Adamas Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02202551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02202551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Lead sponsor
Adamas Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2014
Completion date
February 28, 2018
Enrollment
223 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

dyskinesia, levodopa induced dyskinesia (lid), parkinson's disease (pd)